Tirzepatide (Tirz) is a synthetic peptide analog engineered as a dual agonist of both the GIP and GLP-1 receptors. Designed for preclinical investigations, it has been shown to enhance glucose-stimulated insulin secretion, suppress glucagon release, delay gastric emptying, and reduce inflammatory markers. This multifunctional agent is under evaluation for its roles in metabolic regulation, adipose tissue remodeling, and tissue repair pathways.
For Research Use Only – Not for Human Consumption.